Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 16:10 ET | Source: Bleichmar Fonti & Auld

DXCM CLASS ACTION LAWSUIT: A Securities Fraud Class Action has been filed against DexCom, Inc. – Investors are Notified to Contact BFA Law to Potentially Recover Investment Losses

DexCom, Inc. investors that lost money on their investment are encouraged to contact BFA Law before December 26, 2025 legal deadline.
November 03, 2025 09:00 ET | Source: Wandercraft

Wandercraft Gains Second FDA Indication Extension for Atalante X in Less Than Two Years, Extending Advanced Robotic Rehabilitation for More Patients with Severe Mobility Loss

Wandercraft earns second FDA clearance for expanded indications of Atalante X, enabling rehab for spinal cord injury and multiple sclerosis patients.
November 03, 2025 07:05 ET | Source: uniQure Inc.

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

LEXINGTON, Mass. and AMSTERDAM, Nov. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
November 03, 2025 07:00 ET | Source: Psyence Biomedical Ltd.

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and Ibogaine...
October 30, 2025 08:23 ET | Source: The Ritedose Corporation

Ritedose Now Offers the Largest Nebulized Drug Portfolio in the U.S.: FDA Approves the Company to Manufacture Generic Tobramycin Inhalation Solution

With the addition of Tobramycin Inhalation Solution, Ritedose now provides the largest nebulized drug portfolio in the country.
October 30, 2025 07:55 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Milestone advances MEAI-based therapy targeting a global Alcohol Use Disorder treatment market projected to surpass $20 billion by 2032 Vancouver, Canada, Oct. 30, 2025 (GLOBE NEWSWIRE) -- ...
October 29, 2025 10:00 ET | Source: Dewpoint Therapeutics

FDA Grants Orphan Drug Designation to Dewpoint Therapeutics’ DPTX3186 for the Treatment of Gastric Cancer

Dewpoint's DPTX3186 receives FDA Orphan Drug Designation for gastric cancer - the first ever granted to a condensate-modulating therapeutic.
October 28, 2025 11:05 ET | Source: Nutriband Inc.

REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch

Positive FDA meeting
October 28, 2025 07:00 ET | Source: Nutriband Inc.

Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch

Positive FDA meeting
October 27, 2025 07:00 ET | Source: Nutriband Inc.

Nutriband Co-Founder Gareth Sheridan Returns as CEO

ORLANDO, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company founder, Gareth Sheridan has returned as Company CEO. During the period of...